EVH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Evolent Health Inc (EVH) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is in a bearish trend, with weak financial performance, declining revenue, and negative earnings. Additionally, there are no significant positive catalysts or recent news to support a potential recovery in the near term. Analysts have lowered price targets, and the technical indicators suggest continued downward pressure. While the stock is oversold, the lack of strong trading signals or positive sentiment makes it unsuitable for investment currently.
The technical indicators for EVH are bearish. The MACD histogram is negative and contracting, RSI indicates the stock is oversold at 8.189, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 2.632, and resistance is at 3.3. The stock is trading below its pivot level, suggesting continued downward momentum.
The stock is oversold according to RSI, which may attract short-term traders. Gross margin increased significantly YoY (+93.42%), which could indicate operational improvements.
Analysts have consistently lowered price targets, citing macro challenges and unfavorable trends for value-based care stocks. The stock has a high chance of further decline (-3.76% in the next month).
In Q3 2025, Evolent Health's revenue dropped to $479.53M (-22.83% YoY), net income fell to -$26.93M (-13.77% YoY), and EPS declined to -0.24 (-11.11% YoY). However, gross margin improved to 15.88% (+93.42% YoY), which is a positive sign amidst otherwise weak financials.
Analysts maintain a Buy rating but have significantly lowered price targets recently (e.g., BTIG lowered to $10 from $16, Citi to $9.50 from $11.50, and JPMorgan to $7 from $13). Analysts cite macro challenges and unfavorable trends for value-based care stocks as reasons for the downward revisions.
